ROARABLE
Today ⌘ Pro Terminal Big Ideas 🎲 Predictions Screener πŸ¦‹ Butterfly 8 Analysts πŸ›οΈ Policy 🎬 Video β˜… Watchlist 🎲 Prediction Markets πŸ“Š RQD Track Record πŸ“… Next Catalysts πŸ›‘οΈ Overlap & Crash X-Ray πŸ“° Live Wire πŸ‹ 13F Whales πŸ›οΈ Congress & CEO Buys πŸ† $100K Arena ⌘ Pro Terminal πŸ“ Methodology & Corrections
Stock Ratings / Health Care / BNTX / insiders
EXEL (89) HALO (75) NBIX (73) BIIB (74) ⌘ Pro Terminal β†’

BioNTech SE (BNTX) Insider, 13F Hedge Fund & Politician Buy/Sell Thermometer

$88.17 -1.08% NASDAQ β€’ Live Quote vs Prior Daily Close (Synced Snapshot) EXT / AFTER-HRS: $87.83

BioNTech SE (BNTX) carries a Roarable Rating of D+ (Sell) with 52/100 RQD Confidence due to weak cash-flow efficiency and sensitivity to current interest rates. Wait for business cash flow and institutional buying to improve before committing fresh capital.

πŸ“Š Historical Track Record: Scores of 52/100 (D+) historically posted market-perform odds over rolling 90-day windows (-1.1% avg 90D alpha vs SPY) β†’
ROARABLE D+ β€’ SELL / AVOID Cap $22.39B
πŸ“€ Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card
⚑ INSTANT AI QUANT PREVIEW β€’ $0 FREE TIER Click Any Pre-Computed AI Quant Specialist Briefing on BNTX Below β€” or Connect Your Own ChatGPT / Claude
πŸ€– Mara Quenwick β€’ AI Quant Lead (Click for Instant Brief) Is BNTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?
β–Ό

As of 2026-11-02, BioNTech SE (NASDAQ: BNTX) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 52/100 at a spot price of $88.17 (-1.08% 1D, market cap $22.39B). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 12/20. Across 1016 tracked Health Care issuers, BNTX ranks #262 in composite RQD confidence.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Ellis Vennor β€’ AI Peer & Flow Quant (Click for Instant Brief) How does BNTX compare to EXEL and HALO in the Health Care sector?
β–Ό

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), BNTX carries a Roarable D+ (52/100 RQD), trailing P/E of 32.8x, gross margin of β€”, and ROIC of 9.9%. By comparison, EXEL (Exelixis Inc.) holds a A grade (89/100 RQD, P/E 21.0x, ROIC 35.1%, cap $16.40B) and HALO (Halozyme Therapeutics Inc.) posts a B grade (75/100 RQD, P/E 47.0x, ROIC 18.0%, cap $14.89B). Among the 5-stock peer group, EXEL leads on earnings multiple (21.0x) while EXEL leads on capital efficiency (35.1% ROIC).

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– Gideon Ashmere β€’ AI SEC 10-K Forensics (Click for Instant Brief) What are the biggest fundamental strengths and SEC risk factors for BNTX?
β–Ό

For BioNTech SE (BNTX), key quantitative strengths include Clean SEC annual filing review with no major hidden accounting time-bombs. and sector rank #262 in Health Care, while primary risk factors center on Sensitive to high interest rates and tighter Federal Reserve market liquidity. and implied 5-year growth hurdle of 25.3%/yr. Institutional options positioning shows a 50% call / 50% put premium split.

βœ“ Pre-computed one-to-many AI Quant brief
πŸ€– AI Quant Disclosure: Roarable Analysts are proprietary AI Quant Specialists β€” not human financial advisors. Pre-computed one-to-many briefings above are free; interactive 1-on-1 Q&A, custom AI sifting/indicator alerts, and personal ChatGPT/Claude MCP connections require a $9.95/mo Pro account (currently waitlist-only).
INTERACTIVE SCENARIO DECK:
πŸ›‘οΈ Portfolio Crash X-Ray
EXT / AFTER-HRS: $87.83 (-0.38%)🧬 Cannibal Buyback (-1.24% YoY Shares)βš™οΈ Cash Engine: 11/20 (D+) β€’ 12.4% FCF Margin
Verify 90D Bucket Audit β†’
πŸ“Š Historical Track Record: Scores of 52/100 (D+) historically posted market-perform odds over rolling 90-day windows (-1.1% avg 90D alpha vs SPY β€’ 50.1% hit rate β€” wait for RQD β‰₯ 70 breakout).
Audit Bucket Track Record β†’
RQD QUANT TACHOMETERSELL / AVOID β€’ D+
025507510052
JEV AI Jury Split (Battleground)
Cash
SEC
Whale

Impersonal quantitative research (0–100 RQD rubric) β€” not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw D Β· Rk C-
Cash (11)Whales (5)SEC (16)Macro (8)CEO (12)
Each axis scored 0–20
12M PRICE TARGET CONE-2.7% Base Target
$130 Bull$86 Base$67 Bear
πŸ“¬ FREE BNTX RATING-CHANGE & BRIEFING ALERTSManage / Unsubscribe
WHALE OPTIONS SNAPSHOT: β€” (No Active Options Snapshot on file for BNTX)Realized 20D OHLCV Swing Band: Β±6.4%
Deterministic 5-Pillar Attribution (52/100 Composite)
πŸ” WHY BNTX SCORES 52/100 (D+) β€” TOP 3 DRIVERS2 Bullish Pillars + #1 Risk Drag
β–² #1 Bullish Driver: SEC 10-K Forensic Risk+16/20 pts (31% of score)

Altman Z-Score 3.74 (FORTRESS SAFE (>3.0)) β€’ Piotroski F-Score 8/9

β–² #2 Bullish Driver: Insider Conviction & Share Dilution+12/20 pts (23% of score)

SEC Form 4 / 13F Thermometer: 60% Net Buy β€’ Cannibal Buyback (-1.24% YoY Shares)

β–Ό #1 Drag / Risk Factor: Whale & Options Positioning5/20 pts (-15 pt drag)

Put hedging (50% put share) caps near-term gamma upside (-15 pts vs max)

πŸ“ˆ PAST 4 QUARTERS RQD vs SUBSEQUENT RETURNQ1 β†’ Q2 β†’ Q3 β†’ Current
Q1 (-3Q)
60
Grade C$89.01+2.4% Next Q
Q2 (-2Q)
57
Grade C$91.17-4.5% Next Q
Q3 (-1Q)
55
Grade C$87.06+1.3% Next Q
Current
52
Grade D+$88.17-1.1% Hist 90D Ξ±
Trajectory: C (60) β†’ D+ (52)Full Audit β†’
βš”οΈ ADVERSARIAL OPPOSING CASE & FORENSIC KILL-SWITCH (WHY THE BULL/BEAR THESIS COULD FAIL)CONTRARIAN TURNAROUND & SHORT-SQUEEZE DOSSIER

βš”οΈ Adversarial Opposing Case: What Could Spark a BNTX Turnaround Squeeze

Gideon Ashmere Forensic Desk β†’

While BNTX currently carries a cautious 52/100 (D+) rating due to Whale & Options Positioning (5/20), shorts face asymmetric squeeze risk if free cash flow inflects or management executes accretive buybacks.

πŸš€ Contrarian Squeeze Trigger #1

Clean SEC annual filing review with no major hidden accounting time-bombs.

πŸš€ Contrarian Squeeze Trigger #2

Options & Short-Covering Gamma: Reclaiming the 50-day SMA ($96.22) and Max Pain ($92.58) forces dealer call-delta covering toward $130.20.

πŸš€ Contrarian Squeeze Trigger #3

Forensic Repair Trigger: Halting share dilution (Cannibal Buyback (-1.24% YoY Shares)) or retiring high-cost debt immediately upgrades the SEC 10-K Forensic pillar.

🎲 LIVE PREDICTION MARKET ODDS TIED TO $BNTXβ€’ $2.4M Crowd Pool β€’ Kalshi / Polymarket Composite
Contract: β€œBNTX Beats Next Quarter EPS Consensus (Upcoming Quarter) & Holds Above 200D SMA”
YES 52%NO 48%Trade / Inspect Odds β†’
SEC FORM 4 Γ— 13F HEDGE FUNDS Γ— CONGRESSIONAL STOCK ACT

BNTX Smart-Money Thermometer: BALANCED INSTITUTIONAL POSITIONING

Explore All 13F & Congress Whales β†’
β–² Disclosed Buys: 0 ($0)β–Ό Disclosed Sales: 0 ($0)

Wide-Open SEC Form 4, 13F & Congressional Disclosure Ledger (BNTX)

No recent open-market Form 4 cluster sales or emergency dumps flagged on BNTX. Visit the Global 13F & Congressional Whale Ledger for cross-market smart-money filings.

ON-DEMAND RQD QUANT WORKSHOP β€’ SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Forensic Quant Desk

Red-Light Warning Desk: Spotting SEC Cash-Flow & Dilution Risks Before Downgrades (Featuring BNTX)

  • βœ“Walkthrough of BNTX's RQD Radar, SEC cash-conversion gap & downside invalidation levels
  • βœ“3 asymmetric Bear/Hedge frameworks when 10-year Treasury yields stay elevated
  • βœ“Includes nightly RQD rating-change & forensic signal email alerts on your tracked stocks
RQD INSIDER CLUB WAITLIST$49/YR PLANNED
Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?
Join Founding VIP Waitlist (No Card Required) β†’$100K Arena
BNTX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: -11.25%⚑ TESTING RESISTANCE
2026-11-02O $87.99H $89.13L $87.99C $88.17VOL 692.7K
RES: $89.93SUP: $84.78SMA50: $96.22SMA200: $96.91
$122.8$112.5$102.3$92.03$81.78RES $89.93SUP $84.78$88.172026-05-042026-06-172026-08-042026-09-182026-11-02
PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

BNTX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

πŸ¦‹ BNTX Butterfly Map β†’ + Track BNTX β†’
Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)
25.3%/yr Implied 5Y Growth

vs. +14.3% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on BNTX today. View full Setup Ledger β†’

πŸ¦‹ Documented & Second-Order Butterfly Connections Open Graph β†’

No direct multi-tier Butterfly edges indexed yet for BNTX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video
🎬 No recent verified company-specific video clip queued for BNTX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk β†’
DETERMINISTIC MULTI-FACTOR EQUITY AUDIT β€’ SEC EDGAR XBRL Γ— RQD PEER BENCHMARK

πŸ“Š Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (BNTX)

Health Care Rank #262 of 1016 βš”οΈ EXEL vs BNTX Full Matrix β†’

1. Head-to-Head Health Care Peer Comparison (BNTX vs. EXEL, HALO, NBIX, BIIB)

Industry: Biotechnology: Biological Products (No Diagnostic Substances) (156 Tracked Issuers)

Across 1016 tracked Health Care securities in the Roarable RQD universe, BioNTech SE (BNTX) ranks #262 by composite RQD confidence (52/100, grade D+) and #69 by equity capitalization ($22.39B). Within this direct 5-issuer industry benchmark cohort, EXEL leads on earnings valuation at 21.0x trailing P/E, while EXEL leads on capital efficiency and profitability with 35.1% ROIC and 96.0% gross margin. EXEL currently holds the highest overall quantitative score in the immediate peer group at 89/100 (A) compared with BNTX at 52/100 (D+).

Ticker / Company Roarable Grade RQD Score Trailing P/E Gross Margin ROIC 1D Change Market Cap Head-to-Head
BNTX ACTIVE
BioNTech SE
D+ 52/100 32.8x β€” 9.9% -1.08% $22.39B Benchmark Subject
EXEL
Exelixis Inc.
A 89/100 21.0x 96.0% 35.1% +4.82% $16.40B /exel-vs-bntx β†’
HALO
Halozyme Therapeutics Inc.
B 75/100 47.0x 83.6% 18.0% -0.21% $14.89B /halo-vs-bntx β†’
NBIX
Neurocrine Biosciences Inc.
B 73/100 31.1x 96.0% 15.7% -0.19% $14.88B /nbix-vs-bntx β†’
BIIB
Biogen Inc.
B 74/100 28.5x 75.7% 6.4% +1.59% $36.90B /biib-vs-bntx β†’

2. BNTX Fundamental Profitability, Capital Efficiency & Balance-Sheet Forensics

TRAILING 12M & FORWARD QUANTITATIVE SNAPSHOT

BioNTech SE (BNTX) operates in Biotechnology: Biological Products (No Diagnostic Substances) (Health Care) with an equity capitalization of $22.39B, trailing P/E of 32.8x, forward P/E of 27.6x, and EV/EBITDA of 21.0x. Operating profitability registers a gross margin of β€”, operating margin of 13.9%, net profit margin of 10.9%, ROIC of 9.9%, and free cash flow yield of 2.21%, alongside an Altman Z-Score of 3.74 and Piotroski F-Score of 8/9.

3. BNTX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

βœ“ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is BNTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-02, BioNTech SE (NASDAQ: BNTX) is rated D+ (Sell / SELL) by Roarable's 5-pillar RQD engine with a composite confidence score of 52/100 at a spot price of $88.17 (-1.08% 1D, market cap $22.39B). Pillar breakdown: Fundamental Cash Engine 11/20, Institutional 13F & Options Flow 5/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 8/20, and SEC Balance-Sheet Forensics 12/20. Across 1016 tracked Health Care issuers, BNTX ranks #262 in composite RQD confidence.

How does BNTX compare to EXEL and HALO in the Health Care sector?

Within the Health Care sector (Biotechnology: Biological Products (No Diagnostic Substances)), BNTX carries a Roarable D+ (52/100 RQD), trailing P/E of 32.8x, gross margin of β€”, and ROIC of 9.9%. By comparison, EXEL (Exelixis Inc.) holds a A grade (89/100 RQD, P/E 21.0x, ROIC 35.1%, cap $16.40B) and HALO (Halozyme Therapeutics Inc.) posts a B grade (75/100 RQD, P/E 47.0x, ROIC 18.0%, cap $14.89B). Among the 5-stock peer group, EXEL leads on earnings multiple (21.0x) while EXEL leads on capital efficiency (35.1% ROIC).

What are the biggest fundamental strengths and SEC risk factors for BNTX?

For BioNTech SE (BNTX), key quantitative strengths include Clean SEC annual filing review with no major hidden accounting time-bombs. and sector rank #262 in Health Care, while primary risk factors center on Sensitive to high interest rates and tighter Federal Reserve market liquidity. and implied 5-year growth hurdle of 25.3%/yr. Institutional options positioning shows a 50% call / 50% put premium split.

Where is BNTX trading relative to its 50-day, 200-day, and 52-week technical levels?

BNTX last traded at $88.17 (-1.08% on volume of 631,916 shares), positioning the stock -8.37% below its 50-day simple moving average ($96.22) and -9.02% below its 200-day simple moving average ($96.91). Across its 52-week range of $79.52 to $124.00, BNTX sits at the 19.4% percentile with a 14-day RSI of 43.4 (NEUTRAL RANGE) and an implied next-earnings move of Β±6.4% ($82.53 to $93.81).

BNTX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS β€’ SEC EDGAR Γ— CBOE Γ— FRED

Are BNTX insiders and hedge funds buying or selling?

Roarable's SEC Form 4 and 13F Whale Thermometer currently classifies BNTX leadership and institutional positioning as: BALANCED INSTITUTIONAL POSITIONING.

Direct Sub-Reports: BNTX RQD Cockpit BNTX 12M Forecast BNTX Earnings & Move BNTX Dividends & DRIP BNTX Insiders & 13F BNTX Whale Options BNTX Profit Sankey BNTX News & Why
ROARABLE RATING BRIEF β€’ RQD 52/100 (D+) βœ“ STAGE-C NUMBER FIREWALL VERIFIED

BNTX β€” BioNTech SE: What the Facts Mean to a Prospective Investor

Engine: anthropic/claude-haiku-5.5
As of: 2026-11-02T14:09:28Z

Roarable Rating Brief: What This Means to a Prospective Investor

Per the Roarable RQD rating, BNTX scores 52 out of 100, grade D+, labeled "Roarable Sell β€” Weak Fundamentals / Trim." The five pillars are:

  • Fundamental Cash Engine: 11 / 20 (ROIC 9.9%; FCF yield 2.21%). This is the pillar that most directly reflects economic return on capital. The score indicates modest returns relative to the scale of the business, and the free-cash-flow yield at 2.21% offers limited cash return at the current price.
  • Whale 13F Flow: 5 / 20 (institutional accumulation and options positioning). This is the weakest pillar and signals that institutional positioning is not presently a support for the stock.
  • Insider Conviction: 12 / 20 (SEC Form 4 and Congressional PTR cluster flow). A moderate reading; insider signals are neither strongly supportive nor strongly negative.
  • Macro Regime Fit: 8 / 20 (Beta 1.02; sector sensitivity). Beta of 1.02 means the stock has moved roughly in line with the broader market, and the low pillar score indicates limited alignment with the current macro regime.
  • Forensic Balance Sheet: 16 / 20 (Altman Z 3.74; Piotroski F 8/9; Debt/Equity 0.39). This is the strongest pillar, indicating the balance sheet is a relative strength.

For a prospective investor, the rating frames BNTX as a company with a financially sound balance sheet but weak institutional sponsorship, modest capital returns, and a valuation that carries a premium on earnings (P/E TTM 32.8). The upside case rests on balance-sheet resilience and any improvement in cash generation; the valuation tradeoff is that a 32.8 trailing P/E and 21 EV/EBITDA leave limited margin for error if earnings disappoint. The rating does not constitute personalized financial advice.

Snapshot

PriceMarket CapP/E (TTM)Forward P/EEV/EBITDAEPS (TTM)Dividend YieldBeta52-Wk RangeROIC %
89.13$22.39B32.827.6212.710%1.02$79.52 - $1249.9%

Business

BioNTech SE, trading on NASDAQ under the ticker BNTX as an American Depositary Share, operates in the Health Care sector within the Biotechnology: Biological Products (No Diagnostic Substances) industry. Per the profile, the company's market capitalization is $22.4B. The source data does not describe its products, customers, or revenue model in detail.

Recent Catalysts & News Wire Analysis

Per the recent news feed, six items reference BNTX:

  • A Motley Fool report (YELLOW) asks whether the stock is still a buy following a "major setback" for a cancer vaccine.
  • A Seeking Alpha report (YELLOW) is titled "Moving Past Covid."
  • A Yahoo Finance report (YELLOW) covers stock forecasts.
  • A TradingKey report (YELLOW) notes the stock closed down 7.13% on Oct 13.
  • A TradingView report (YELLOW) covers analyst estimates.
  • A Benzinga report (RED, RISK WATCH) asks why the stock is falling on a Tuesday.

The Benzinga item is the only RISK WATCH flag in the feed. No proprietary signals are present in the Butterfly graph. The feed summaries are generic and do not disclose the specific cause of the cited declines or setbacks.

Open Questions

  • What specific setback affected the cancer vaccine program referenced in the news feed, and what is its financial significance?
  • What are the reported revenue, operating income, and free cash flow across recent periods to confirm the margin and FCF yield trends?
  • What is the analyst consensus rating and price target distribution, and how does the current $89.13 price compare?
  • What institutional (13F) and insider (Form 4) positioning exists, given the Whale 13F pillar scored 5 of 20?
  • What drove the 52-week range of $79.52 to $124, and where does the current price sit within that range over time?

BNTX Live News Feed, Press Releases & Catalyst Wire

Real-time company headlines, analyst actions, and sector developments for BioNTech SE (BNTX) β€’ Click "Debate This Headline" to argue it in the Roar Pit below

πŸ’¬ Jump to BNTX Debate Forum (3) ↓
πŸ”₯ THE ROAR PIT β€’ LIVE COMMUNITY DEBATE 3 Active Posts & Replies

BNTX Bull vs. Bear Conversation Board β€” What's Your Call at $88.17?

πŸ‚ 50% BULLISH CONVICTION COMMUNITY TUG-OF-WAR ON BNTX 🐻 50% BEARISH CONVICTION
1. Pick Your Side on BNTX:
πŸ’‘ Tip: Back up your call with a price target or RQD metric to get upvoted to the top.
RO RoarDesk_Moderator Roarable Research Desk βš–οΈ DEBATE HOST 🎯 Target: $96.26 (+8.0%)
πŸ“Œ Pinned Debate

πŸ”₯ Official Bull vs. Bear Debate: Is BNTX (D+ β€’ RQD 52/100) a Buy at $89.13?

Welcome to the BNTX (BioNTech SE) Roar Pit. Current RQD Composite is 52/100 (Roarable Sell β€” Weak Fundamentals / Trim) in Biotechnology: Biological Products (No Diagnostic Substances). Bulls point to operating leverage and sector positioning, while bears focus on valuation multiple compression (32.8x trailing P/E). Pick your side (πŸ‚ Bull or 🐻 Bear) and drop your price target below.

SH ShortSeller_Dan Forensic Accounting Watch 🐻 BEARISH 🎯 Target: $66.85 (-25.0%)
Spot @ $89.13

Pump the brakes on BNTX β€” check the valuation vs. margin headwinds

Everyone in here is repeating the bull case on BNTX, but look at what you are paying: 32.8x trailing P/E with tightening sector spreads. Unless BioNTech SE expands free cash flow yield next quarter, I would rather wait for a pullback closer to the 200-day moving average before touching this.

QU QuantViper Verified K Arena Trader πŸ‚ BULLISH 🎯 Target: $114.09 (+28.0%)
Spot @ $89.13

BNTX cash flow & RQD setup is being underpriced by the Street here

Looking at the 5-pillar RQD breakdown on BNTX, the market is fixating on short-term headline noise in Biotechnology: Biological Products (No Diagnostic Substances) and ignoring the balance sheet and cash flow trajectory. At $89.13 (52-wk range $79.52 - $124.00), any beat on forward guidance forces shorts and underweight funds to chase.

LIVE TAPE SPY $755.72 -0.38% QQQ $690.49 -1.44% DIA $517.13 -0.37% IWM $279.33 +0.96% NVDA $204.64 -4.22% AAPL $344.63 -1.23% MSFT $521.91 -1.55% TSLA $399.81 -0.86% PLTR $184.11 -6.27% SOFI $16.76 -4.83% IBIT $43.36 -0.94% GLD $355.78 -1.34%